Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Goldman Sachs Group Inc

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Goldman Sachs Group Inc

149
0
SHARE

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “neutral” rating reaffirmed by investment analysts at Goldman Sachs Group Inc in a research report issued to clients and investors on Wednesday. They presently have a $64.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $44.00. Goldman Sachs Group Inc’s target price points to a potential downside of 9.97% from the company’s previous close.

A number of other research firms have also recently weighed in on ALNY. Vetr cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price objective on the stock. in a research report on Monday. Piper Jaffray Companies set a $118.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. Chardan Capital cut their price objective on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday. Credit Suisse Group AG cut shares of Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 price objective on the stock. in a research report on Monday, March 20th. Finally, BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, April 17th. They set an “outperform” rating and a $73.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $70.97.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 71.09 on Wednesday. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $80.11. The company’s 50 day moving average is $53.82 and its 200 day moving average is $46.81. The company’s market cap is $6.13 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The firm had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. During the same quarter last year, the firm earned ($1.21) EPS. The company’s revenue was up 160.3% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals will post ($5.35) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was reported by [[site]] and is the sole property of of [[site]]. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at [[permalink]].

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now directly owns 5,625 shares in the company, valued at approximately $393,750. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Akshay Vaishnaw sold 43,750 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the transaction, the senior vice president now owns 43,047 shares in the company, valued at $2,798,055. The disclosure for this sale can be found here. 4.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Janus Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 25.5% in the first quarter. Janus Capital Management LLC now owns 649,399 shares of the biopharmaceutical company’s stock valued at $33,280,000 after buying an additional 131,969 shares during the last quarter. Credit Suisse AG boosted its position in shares of Alnylam Pharmaceuticals by 39.0% in the first quarter. Credit Suisse AG now owns 248,364 shares of the biopharmaceutical company’s stock valued at $12,729,000 after buying an additional 69,697 shares during the last quarter. Blue Ridge Capital L.L.C. boosted its position in shares of Alnylam Pharmaceuticals by 20.5% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock valued at $81,488,000 after buying an additional 270,000 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. Finally, KCG Holdings Inc. boosted its position in shares of Alnylam Pharmaceuticals by 8.1% in the first quarter. KCG Holdings Inc. now owns 31,800 shares of the biopharmaceutical company’s stock valued at $1,630,000 after buying an additional 2,374 shares during the last quarter. Institutional investors own 88.70% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

5 Day Chart for NASDAQ:ALNY

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

SHARE
Dan specializes in matters of money management and personal finance and has been published on numerous financial, business, health and wellness and sports websites.

LEAVE A REPLY